Salt forms with tyrosine kinase activity
OwnerYu Ren, Shyam B. Karki +2inventors
InventorsYu Ren, Shyam B. Karki, Matthew M. Zhao, Mark T. Bidodeau
Life of this patent
Estimating the term…
Abstract
The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
Claims53
A polymorphous form of a hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.
A hydrochloride ethanolate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide characterized by an X-ray powder diffraction pattern having diffraction angles of:
- 6.09, 10.96, 12.03, 16.52, 16.79, 17.99, 18.31, 18.41, 19.87, 20.01, 21.42, 21.63, 24.82, 25.04, 25.44, 25.81, 27.16, 29.92, 34.89, and 36.43.
A tartrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide characterized by an X-ray powder diffraction pattern having diffraction angles of:
- 10.22, 11.14, 13.44, 14.28, 16.76, 22.86, 24.98, 25.94, 28.72, and 29.86.
A polymorphous form of a citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.
A polymorphous form of a besylate salt of of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.
The method of claim 61 wherein the GPIIb/IIIa antagonist is tirofiban.
Dependencies are inferred from the claim text.